Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein

Table 5 Factors affecting overall survival using Cox’s proportional hazard model

Factor	Univariate analysis				Multivariate analysis
	Patients, n	Mean OS (mo)	95%CI	P value	HR	95%CI	P value
Positive for HBsAg
Yes	349	9.05	8.33-9.76	0.035	1.09	0.56-2.14	0.798
No	69	10.58	9.92-11.23
Positive for anti-HCV
Yes	19	6.00	2.49-9.51	0.026	1.45	0.44-3.88	0.454
No	399	9.42	8.90-9.94
AFP (mg/L)
> 400	134	7.99	6.94-9.05	< 0.001	1.84	1.09-3.11	0.023
≤ 400	284	9.96	9.42-10.49
Child-Pugh Stage
Stage A	262	9.88	9.34-10.42	< 0.001	1.99	1.20-3.30	0.008
Stage B	156	8.28	7.21-9.37
Tumor size (cm)
> 5	301	8.48	7.79-9.18	< 0.001	3.31	1.57-6.98	0.002
≤ 5	117	10.82	10.20-11.45
Tumor number
> 3	147	8.62	7.92-9.32	< 0.001	2.10	1.22-3.63	0.007
≤ 3	271	10.55	9.89-11.20
Cirrhosis
Yes	343	8.85	8.23-9.46	0.007	2.10	1.02-4.32	0.044
No	75	10.82	10.06-11.59
Portal hypertension
Yes	113	7.00	6.03-7.98	< 0.001	1.65	1.02-2.65	0.041
No	345	10.14	9.62-10.65
Tumor thrombus location
Main portal vein trunk	299	10.40	9.89-10.91	< 0.001	4.51	2.66-7.65	< 0.001
Inferior vena cava	119	4.83	4.26-5.41

PVTT: Portal vein tumor thrombus; HBsAg: Hepatitis B surface antigen; anti-HCV: Hepatitis C virus antibody; PLT: Platelet count; TBil: Total bilirubin; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PT: Prothrombin time; AFP: Alpha-fetoprotein.